eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank

1/2023
vol. 15
 
Share:
Share:
abstract:
Original paper

HDR-brachytherapy for accelerated partial breast irradiation: Long-term experience from a Japanese institution

Ken Yoshida
1, 2
,
Tadayuki Kotsuma
2, 3
,
Yuji Takaoka
2, 4
,
Setsuo Tamenaga
2
,
Hideya Yamazaki
5
,
Takayuki Nose
6
,
Naoya Murakami
7
,
Koji Inaba
7
,
Hironori Akiyama
8
,
Koji Masui
9
,
Tadashi Takenaka
5
,
Hikaru Kubota
2, 10
,
Nikolaos Tselis
11
,
Norikazu Masuda
12
,
Hiroyuki Yasojima
13
,
Masashi Takeda
14
,
Masayuki Mano
15
,
Satoaki Nakamura
16
,
Keita Utsunomiya
1
,
Noboru Tanigawa
17
,
Eiichi Tanaka
2

1.
Department of Radiology, Kansai Medical University Medical Center, Osaka, Japan
2.
Department of Radiation Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
3.
Department of Radiation Oncology, Osaka Rosai Hospital, Osaka, Japan
4.
Department of Radiology, Saito Yukoukai Hospital, Osaka, Japan
5.
Department of Radiology, Kyoto Prefectural University of Medicine, Kyoto, Japan
6.
Department of Radiation Oncology, Nippon Medical School Tamanagayama Hospital, Tokyo, Japan
7.
Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan
8.
Department of Oral radiology, Osaka Dental University, Osaka, Japan
9.
Department of Radiology, Fukuchiyama City Hospital, Kyoto, Japan
10.
Division of Radiation Oncology, Kobe University Hospital, Hyogo, Japan
11.
Department of Radiation Oncology, Johann Wolfgang Goethe University Frankfurt, Frankfurt, Germany
12.
Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Aichi, Japan
13.
Department of Surgery, Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan
14.
Department of Pathology, Wakakusa Daiichi Hospital, Osaka, Japan
15.
Department of Central Laboratory and Surgical Pathology, National Hospital Organization Osaka National Hospital, Osaka, Japan
16.
Division of Radiation Oncology, Kansai Medical University Hospital, Osaka, Japan
17.
Department of Radiology, Kansai Medical University Hospital, Osaka, Japan
J Contemp Brachytherapy 2023; 15, 1: 1–8
Online publish date: 2023/02/28
View full text Get citation
 
Purpose:
We investigated the long-term oncological outcome of high-dose-rate (HDR) multicatheter interstitial brachytherapy (MIB) for adjuvant accelerated partial breast irradiation (APBI) after breast conserving surgery in Japanese patients.

Material and methods:
Between June 2002 and October 2011, 86 breast cancer patients were treated at National Hospital Organization Osaka National Hospital (trial number of the local institutional review board, 0329). Median age was 48 years (range, 26-73 years). Eighty patients had invasive and 6 patients non-invasive ductal carcinoma. Tumor stage distribution was pT0 in 2, pTis in 6, pT1 in 55, pT2 in 22, and pT3 in one patient, respectively. Twenty-seven patients had close/positive resection margins. Total physical HDR dose was 36-42 Gy in 6-7 fractions.

Results:
At a median follow-up of 119 months (range, 13-189 months), the 10-year local control (LC) and overall survival rate was 93% and 88%, respectively. Concerning the 2009 Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology risk stratification scheme, the 10-year LC rate was 100%, 100%, and 91% for patients considered as low-risk, intermediate-risk, and high-risk, respectively. According to the 2018 American Brachytherapy Society risk stratification scheme, the 10-year LC rate was 100% and 90% for patients ‘acceptable’ and ‘unacceptable’ for APBI, respectively. Wound complications were observed in 7 patients (8%). Risk factors for wound complications were the omission of prophylactic antibiotics during MIB, open cavity implantation, and V100 ≥ 190 cc. No grade ≥ 3 late complications (CTCVE version 4.0) were observed.

Conclusions:
Adjuvant APBI using MIB is associated with favorable long-term oncological outcomes in Japanese patients for low-risk, intermediate-risk, and acceptable groups of patients.

keywords:

APBI, breast conserving surgery, wound complication

 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.